Crescent Biopharma, Inc.
CBIOHealthcareNASDAQBiotechnology · Last scanned May 30, 2026
Scan Results
Daily timeframeHeadquartered within the healthcare sector, Crescent Biopharma, Inc. focuses on Biotechnology services and products. Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. The $569.4M market capitalization puts CBIO squarely in small-cap range for its industry. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003.
Market Cap
$569.4M
Beta
—
P/E (TTM)
—
P/E (Fwd)
-7.02
EPS (TTM)
$-5.88
EPS (Fwd)
$-2.94
ROE
—
ROA
—
Cash
$189.2M
Total Debt
$1.5M
Free CF
—
52W Change
3.3%
Annual Financials
Cash vs Debt
With $189.2M in cash and $1.5M in debt, CBIO maintains more liquidity than leverage. This favorable balance sheet position can be an asset when capital markets become less accommodating.
With cash comfortably exceeding debt, CBIO has financial flexibility that may help navigate uncertain periods. No single metric tells the full story. Reviewing CBIO's risk profile alongside its fundamentals and technical indicators provides a more complete picture.